In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Immunome (IMNM – Research Report). The company’s shares closed last Friday at $15.50.
According to TipRanks, Van Buren is a 3-star analyst with an average return of 1.0% and a 44.62% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as Regeneron, Spyre Therapeutics, and BridgeBio Pharma.
Immunome has an analyst consensus of Strong Buy, with a price target consensus of $32.50, implying a 109.68% upside from current levels. In a report released on April 30, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $24.00 price target.
Based on Immunome’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.83 million and a GAAP net loss of $92.6 million. In comparison, last year the company had a GAAP net loss of $7.74 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immunome (IMNM) Company Description:
Immunome Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody-based drugs. The company’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients who have learned to fight off their disease. It is developing treatments for treating cancer and other infectious diseases.
